Literature DB >> 25920920

Lupus nephritis management guidelines compared.

Suzanne Wilhelmus1, Ingeborg M Bajema1, George K Bertsias2, Dimitrios T Boumpas3, Caroline Gordon4, Liz Lightstone5, Vladimir Tesar6, David R Jayne7.   

Abstract

In the past years, many (randomized) trials have been performed comparing the treatment strategies for lupus nephritis. In 2012, these data were incorporated in six different guidelines for treating lupus nephritis. These guidelines are European, American and internationally based, with one separate guideline for children. They offer information on different aspects of the management of lupus nephritis including induction and maintenance treatment of the different histological classes, adjunctive treatment, monitoring of the patient, definitions of response and relapse, indications for (repeat) renal biopsy, and additional challenges such as the presence of vascular complications, the pregnant SLE patient, treatment in children and adolescents and considerations about end-stage renal disease and transplantation. In this review, we summarize the guidelines, determine the common ground between them, highlight the differences and discuss recent literature.
© The Author 2015. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Entities:  

Keywords:  guideline; lupus nephritis; management; systemic lupus erythematosus; treatment

Mesh:

Year:  2015        PMID: 25920920     DOI: 10.1093/ndt/gfv102

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  27 in total

1.  [Lupus nephritis].

Authors:  S Melderis; T Wiech; C Iking-Konert; O M Steinmetz
Journal:  Z Rheumatol       Date:  2018-09       Impact factor: 1.372

2.  Immunosuppressive treatment for pure membranous lupus nephropathy in a Hispanic population.

Authors:  Juan Manuel Mejía-Vilet; Bertha M Córdova-Sánchez; Norma O Uribe-Uribe; Ricardo Correa-Rotter
Journal:  Clin Rheumatol       Date:  2016-07-30       Impact factor: 2.980

3.  Systemic lupus erythematosus: Extent and patterns of off-label use of rituximab for SLE.

Authors:  Iñaki Sanz
Journal:  Nat Rev Rheumatol       Date:  2016-11-22       Impact factor: 20.543

Review 4.  Targeting DAMPs with nucleic acid scavengers to treat lupus.

Authors:  Lyra B Olson; Nicole I Hunter; Rachel E Rempel; Bruce A Sullenger
Journal:  Transl Res       Date:  2022-03-02       Impact factor: 10.171

5.  History of proliferative glomerulonephritis predicts end stage kidney disease in pure membranous lupus nephritis.

Authors:  Andrea Fava; Paride Fenaroli; Avi Rosenberg; Serena Bagnasco; Jessica Li; Jose Monroy-Trujillo; Derek Fine; Mohamed G Atta; Michelle Petri
Journal:  Rheumatology (Oxford)       Date:  2022-05-30       Impact factor: 7.046

Review 6.  Insights into the epidemiology and management of lupus nephritis from the US rheumatologist's perspective.

Authors:  Paul J Hoover; Karen H Costenbader
Journal:  Kidney Int       Date:  2016-06-22       Impact factor: 10.612

7.  Outcomes of rituximab therapy in refractory lupus: A meta-analysis.

Authors:  Fatma Alshaiki; Elaf Obaid; Abdulqader Almuallim; Rabab Taha; Hadeel El-Haddad; Hani Almoallim
Journal:  Eur J Rheumatol       Date:  2018-02-13

8.  Urinary MCP-1 and TWEAK as non-invasive markers of disease activity and treatment response in patients with lupus nephritis in South Africa.

Authors:  Mothusi W Moloi; Jody A Rusch; Fierdoz Omar; Udeme Ekrikpo; Collet Dandara; Aminu K Bello; David Jayne; Ikechi G Okpechi
Journal:  Int Urol Nephrol       Date:  2021-01-18       Impact factor: 2.370

9.  LangChuangHeJi decoction ameliorates lupus via preventing accumulation of CD138+ T cells in MRL/lpr mice.

Authors:  Tianhong Xie; Xin Liu; Huiqiang Liu; Xuyang Han; Jingxia Zhao; Dongmei Zhou; Yan Wang; Hongkai Zhang; Ping Wang; Ping Li
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

10.  The extent of tubulointerstitial inflammation is an independent predictor of renal survival in lupus nephritis.

Authors:  Ricard Cervera; Luis F Quintana; Manuel Ferreira Gomes; Claudia Mardones; Marc Xipell; Miquel Blasco; Manel Solé; Gerard Espinosa; Adriana García-Herrera
Journal:  J Nephrol       Date:  2021-03-15       Impact factor: 3.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.